A lower percentage of patients with diabetes experienced a 50% or greater reduction from baseline PSA following ADT, and a lower percentage of patients with diabetes reached a nadir PSA <0.2 ng/mL following ADT, though neither of these observations reached statistical significance. This evidence concerns the gene KLK3 and diabetes mellitus.